PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Scientists pinpoint a new line of defence used by cancer cells

Scientists pinpoint a new line of defence used by cancer cells
2014-12-08
(Press-News.org) Cancer Research UK scientists have discovered a new line of defence used by cancer cells to evade cell death, according to research published in Nature Communications* today (Monday).

The team identified a critical pathway of molecular signals which throw a lifeline to cancer cells, enabling them to survive even though they contain vast DNA errors which would usually trigger cell death.

The PKCƐ signal pathway**, which is used by cancer cells but rarely by normal cells, could be important in targeting some cancer cells as they rely on this pathway to survive.

The pathway helps the cancer cells survive by allowing them to untangle and separate their DNA. Cancer cells rely on this signal pathway more than normal cells because their DNA is more jumbled and prone to becoming tangled.

Turning off the pathway can trigger cancer cells to self-destruct because the machinery used to untangle the DNA fails, meaning it is torn apart as the cell divides - ravaging and causing huge breaks in the code which lead to the cancer cells' demise.

VIDEO: A cell's ability to divide in two is fundamental to life. These white blobs show DNA being separated as cells divide. But if mistakes are made, this can lead to...
Click here for more information.

Lead researcher Dr Nicola Brownlow, Cancer Research UK scientist at the Cancer Research UK London Research Institute, said: "Taking out this line of defence could be a powerful way to target the disease and re-programme cancer cells to self-destruct.

"The next step in our research is to understand which cancer types have this weak spot and to look for a marker that will allow us to test patients for cancers with this fault."

Nell Barrie, Cancer Research UK's senior science information manager, said: "This research has uncovered an important weakness which we could use to tackle cancer. Newer, precise methods which target the dents in cancer's armoury provide fresh opportunities for better treatments to help more people survive the disease.

"There's still a lot of work to do before this research leads to a new cancer treatment, but it offers us a new strategy to beat the disease by helping us to understand what causes and drives cancer."

INFORMATION:

For media enquiries contact Stephanie McClellan in the Cancer Research UK press office on 020 3469 5314 or, out of hours, on 07050 264 059.

Notes to editors:

* Brownlow et al. Mitotic catenation is monitored and resolved by a PKCε-regulated pathway. Nature Communications. DOI: 10.1038/ncomm6685. ** Also known as the Protein Kinase C epsilon (PKCƐ) pathway.

Images and video available: You can download a video of the research here: http://bit.ly/1AmGw9H

Images are also available please contact the press office to request these.

About Cancer Research UK Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research. Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives. Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated. Cancer Research UK has been at the heart of the progress that has already seen survival rates in the UK double in the last forty years. Today, 2 in 4 people survive cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that 3 in 4 people will survive cancer within the next 20 years. Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses. Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.

For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.cancerresearchuk.org. Follow us on Twitter and Facebook.


[Attachments] See images for this press release:
Scientists pinpoint a new line of defence used by cancer cells Scientists pinpoint a new line of defence used by cancer cells 2 Scientists pinpoint a new line of defence used by cancer cells 3

ELSE PRESS RELEASES FROM THIS DATE:

Unusual electronic state found in new class of unconventional superconductors

Unusual electronic state found in new class of unconventional superconductors
2014-12-08
UPTON, NY-A team of scientists from the U.S. Department of Energy's (DOE) Brookhaven National Laboratory, Columbia Engineering, Columbia Physics and Kyoto University has discovered an unusual form of electronic order in a new family of unconventional superconductors. The finding, described in the journal Nature Communications, establishes an unexpected connection between this new group of titanium-oxypnictide superconductors and the more familiar cuprates and iron-pnictides, providing scientists with a whole new family of materials from which they can gain deeper insights ...

Most elderly women with early stage breast cancer receive a treatment that may not be as effective

2014-12-08
A new analysis has found that while clinical trial data support omitting radiation treatments in elderly women with early stage breast cancer, nearly two-thirds of these women continue to receive it. The findings are published early online in Cancer, a peer-reviewed journal of the American Cancer Society. Results published in 2004 from a large, randomized clinical trial showed that adding radiation therapy to surgery plus tamoxifen does not reduce 5-year recurrence rates or prolong survival in elderly women with early stage tumors. Despite the findings, many doctors still ...

Older breast cancer patients still get radiation despite limited benefit

2014-12-08
DURHAM, N.C. - Women over the age of 70 who have certain early-stage breast cancers overwhelmingly receive radiation therapy despite published evidence that the treatment has limited benefit, researchers at Duke Medicine report. The study suggests that doctors and patients may find it difficult to withhold treatment previously considered standard of care, even in the setting of high quality data demonstrating that the advantages are small. "The onus is on physicians to critically analyze data to shape our treatment recommendations for patients, weighing the potential ...

Scientists reveal parchment's hidden stories

Scientists reveal parchments hidden stories
2014-12-08
Dublin, IRELAND Monday December 8th, 2014 - Millions of documents stored in archives could provide scientists with the key to tracing agricultural development across the centuries, according to new research completed at Trinity College Dublin and the University of York. Amazingly, thanks to increasingly progressive genetic sequencing techniques, the all-important historical tales these documents tell are no longer confined to their texts; now, vital information also comes from the DNA of the parchment on which they are written. Researchers used these state-of-the-art ...

Correcting metabolic abnormalities may help lessen urinary problems

2014-12-08
Metabolic syndrome is linked with an increased frequency and severity of lower urinary tract symptoms, but weight loss surgery may lessen these symptoms. The findings, which come from two studies published in BJU International, indicate that urinary problems may be added to the list of issues that can improve with efforts that address altered metabolism. Lower urinary tract symptoms related to urinary frequency and urgency, bladder leakage, the need to urinate at night, and incomplete bladder emptying are associated with obesity in both men and women. To see if these ...

Dartmouth/Univ. of Exeter Study: Correcting myths about the flu vaccine

2014-12-08
HANOVER, N.H. - December 8, 2014 - With health systems in the U.S., U.K., and around the world trying to increase vaccination levels, it is critical to understand how to address vaccine hesitancy and counter myths about vaccine safety. A new article in the journal "Vaccine" concludes, however, that correcting myths about vaccines may not be the most effective approach to promoting immunization among vaccine skeptics. The study, which was co-authored by Brendan Nyhan, an assistant professor of government at Dartmouth College, and Jason Reifler, a senior lecturer of politics ...

Penn researchers announce latest results of investigational cellular therapy

2014-12-08
SAN FRANCISCO - The latest results of clinical trials of more than 125 patients testing an investigational personalized cellular therapy known as CTL019 will be presented by a University of Pennsylvania research team at the 56th American Society of Hematology Annual Meeting and Exposition. Highlights of the new trial results will include a response rate of more than 90 percent among pediatric acute lymphoblastic leukemia patients, and results from the first lymphoma trials testing the approach, including a 100 percent response rate among follicular lymphoma patients and ...

Narrow subset of cells is responsible for metastasis in multiple myeloma, study finds

2014-12-08
Although it is among the most highly metastatic of all cancers, multiple myeloma is driven to spread by only a subset of the myeloma cells within a patient's body, researchers at Dana-Farber Cancer Institute have found in a study presented at the annual meeting of the American Society of Hematology (ASH). The study suggests that attacking those subsets with targeted drugs may degrade the disease's ability to spread throughout the bone marrow of affected patients, the authors say. The discovery was made by developing a mouse model of the disease that enabled researchers ...

Oral inhibitor shows clinical activity in poor-prognosis AML

2014-12-08
An oral targeted drug has shown encouraging activity and tolerable side effects in patients with treatment-resistant or relapsed acute myelogenous leukemia (AML) - a poor-prognosis group with few options - report investigators from Dana-Farber Cancer Institute and M.D. Anderson Cancer Center.   Of 32 patients treated with the oral inhibitor ABT-199, five had eradication of their leukemia and several more had stable disease, according to Anthony Letai, MD, PhD, of Dana-Farber, senior author of the report.     The phase 2 multicenter trial was the first ...

Combination therapy shown as effective for higher-risk MDS/AML patients

Combination therapy shown as effective for higher-risk MDS/AML patients
2014-12-08
A phase two study that investigated the potential of the drugs azacitidine (AZA) and lenalidomide (LEN), demonstrated that the two therapies in combination may be an effective frontline treatment regimen for patients with higher-risk forms of myelodysplastic syndrome and acute myeloid leukemia. Myelodysplastic syndrome (MDS) is a type of cancer in which the bone marrow does not make enough healthy blood cells, resulting in abnormal (blast) cells in the blood and/or bone marrow. Higher-risk patients experience an unusually large percentage of blasts in their blood. Patients ...

LAST 30 PRESS RELEASES:

The simulated Milky Way: 100 billion stars using 7 million CPU cores

Brain waves’ analog organization of cortex enables cognition and consciousness, MIT professor proposes at SfN

Low-glutamate diet linked to brain changes and migraine relief in veterans with Gulf War Illness

AMP 2025 press materials available

New genetic test targets elusive cause of rare movement disorder

A fast and high-precision satellite-ground synchronization technology in satellite beam hopping communication

What can polymers teach us about curing Alzheimer's disease?

Lead-free alternative discovered for essential electronics component

BioCompNet: a deep learning workflow enabling automated body composition analysis toward precision management of cardiometabolic disorders

Skin cancer cluster found in 15 Pennsylvania counties with or near farmland

For platforms using gig workers, bonuses can be a double-edged sword

Chang'e-6 samples reveal first evidence of impact-formed hematite and maghemite on the Moon

New study reveals key role of inflammasome in male-biased periodontitis

MD Anderson publicly launches $2.5 billion philanthropic campaign, Only Possible Here, The Campaign to End Cancer

Donors enable record pool of TPDA Awards to Neuroscience 2025

Society for Neuroscience announces Gold Sponsors of Neuroscience 2025

The world’s oldest RNA extracted from woolly mammoth

Research alert: When life imitates art: Google searches for anxiety drug spike during run of The White Lotus TV show

Reading a quantum clock costs more energy than running it, study finds

Early MMR vaccine adoption during the 2025 Texas measles outbreak

Traces of bacteria inside brain tumors may affect tumor behavior

Hypertension affects the brain much earlier than expected

Nonlinear association between systemic immune-inflammation index and in-hospital mortality in critically ill patients with chronic obstructive pulmonary disease and atrial fibrillation: a cross-sectio

Drift logs destroying intertidal ecosystems

New test could speed detection of three serious regional fungal infections

New research on AI as a diagnostic tool to be featured at AMP 2025

New test could allow for more accurate Lyme disease diagnosis

New genetic tool reveals chromosome changes linked to pregnancy loss

New research in blood cancer diagnostics to be featured at AMP 2025

Analysis reveals that imaging is overused in diagnosing and managing the facial paralysis disorder Bell’s palsy

[Press-News.org] Scientists pinpoint a new line of defence used by cancer cells